Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced tha...
Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions to the life sciences industry, has joined forces with Sanof...
The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults1.There...
Omniose, a preclinical stage biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca for the search for potential vacc...
- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust imm...
The priority categorization, established by the WHO in collaboration with UNICEF and the Revolving Fund of the Pan American Health Organization, is based o...
-Sail Biomedicines, Inc. (“Sail” or the “Company”), a Flagship Pioneering company and leader in RNA-based programmable medicines, a...
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Afr...
The chikungunya virus is primarily transmitted to people through the bite of an infected mosquito. Chikungunya is an emerging global health threat with at ...
H.E Dr. Jean Kaseya, Director General of the African Centers for Disease Control and Prevention (Africa CDC), visited SK bioscience t...
Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 an...
VLA1553 is currently the first and only chikungunya vaccine candidate worldwide for which regulatory review processes are underway. A Biologic License Appl...
.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression f...
The move builds on lessons the foundation has learned from more than 20 years of working with vaccine manufacturers in LMICs and the opportunity to leverag...
© 2024 Biopharma Boardroom. All Rights Reserved.
